LON:OXB - Oxford BioMedica Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 700.60 -3.40 (-0.48 %) (As of 03/21/2019 01:19 AM ET)Previous CloseGBX 704Today's RangeGBX 696 - GBX 70752-Week RangeGBX 511 - GBX 1,062.60Volume95,243 shsAverage Volume6.89 million shsMarket Capitalization£463.30 millionP/E Ratio-875.75Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartInsider TradesHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and retinal cells in the eye, as well as accommodates multiple therapeutic genes. The company's products under development include OXB-102 that is in Phase I/IIa study preparation for the treatment of Parkinson's disease; OXB-202, which is in a Phase I/IIa trial preparation for the prevention of corneal graft rejection; and OXB-302, a gene-based cancer immunotherapy product that has completed pre-clinical development for use in the treatment of a range of cancers, as well as OXB-201 that has completed Phase I trial for the treatment of wet age-related macular degeneration and diabetic retinopathy. It is also developing gene-based therapies, such as SAR 422459 that is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869, which is in Phase I/II trial for the treatment of Usher syndrome 1B. The company has partnerships with Novartis, Sanofi, GlaxoSmithKline, Bioverativ, Orchard Therapeutics, GC LabCell, the UK Cystic Fibrosis Gene Therapy Consortium, Imperial Innovations, and Immune Design. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom. Receive OXB News and Ratings via Email Sign-up to receive the latest news and ratings for OXB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:OXB Previous Symbol CUSIPN/A CIKN/A Webwww.oxfordbiomedica.co.uk Phone+44-1865-783000Debt Debt-to-Equity Ratio124.13 Current Ratio2.25 Quick Ratio2.05Price-To-Earnings Trailing P/E Ratio-875.75 Forward P/E Ratio-10,008.57 P/E GrowthN/A Sales & Book Value Annual Sales£57.18 million Price / Sales8.10 Cash FlowGBX 71.96 per share Price / Cash Flow9.74 Book ValueGBX 48.60 per share Price / Book14.42Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares66,129,700Market Cap£463.30 million Next Earnings DateN/A OptionableNot Optionable Oxford BioMedica (LON:OXB) Frequently Asked Questions What is Oxford BioMedica's stock symbol? Oxford BioMedica trades on the London Stock Exchange (LON) under the ticker symbol "OXB." What price target have analysts set for OXB? 2 equities research analysts have issued twelve-month target prices for Oxford BioMedica's shares. Their forecasts range from GBX 16 to GBX 16. On average, they expect Oxford BioMedica's stock price to reach GBX 16 in the next year. This suggests that the stock has a possible downside of 97.7%. View Analyst Price Targets for Oxford BioMedica. What is the consensus analysts' recommendation for Oxford BioMedica? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford BioMedica in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oxford BioMedica. Has Oxford BioMedica been receiving favorable news coverage? News stories about OXB stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Oxford BioMedica earned a news impact score of -1.4 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are some of Oxford BioMedica's key competitors? Some companies that are related to Oxford BioMedica include Genus (GNS), Clinuvel Pharmaceuticals (CUV), Concordia International (CXR), Mesoblast (MSB), Resverlogix (RVX), Emerald Health Therapeutics (EMH), Theratechnologies (TH), Biotest (BIO), Polynovo (PNV), Senesco Technologies (ELOX), Starpharma (SPL), Neptune Wellness Solutions (NEPT), IMV (IMV), Enochian Biosciences (ENOB) and Monash IVF Group (MVF). What other stocks do shareholders of Oxford BioMedica own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford BioMedica investors own include Petra Diamonds (PDL), Sirius Minerals (SXX), Enquest (ENQ), Lloyds Banking Group (LLOY), Oxford BioMedica (OXBDF), Barclays (BARC), Advanced Oncotherapy (AVO), Centamin (CEY), Ilika (IKA) and Jubilee Metals Group (JLP). Who are Oxford BioMedica's key executives? Oxford BioMedica's management team includes the folowing people: Mr. John Dawson, CEO & Exec. Director (Age 59)Mr. Stuart Paynter, CFO & DirectorMr. Timothy William Watts, Exec. Officer (Age 61)Mr. Peter Nolan, Consultant (Age 66)Mr. Nick Page, Chief Operations Officer How do I buy shares of Oxford BioMedica? Shares of OXB and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Oxford BioMedica's stock price today? One share of OXB stock can currently be purchased for approximately GBX 700.60. How big of a company is Oxford BioMedica? Oxford BioMedica has a market capitalization of £463.30 million and generates £57.18 million in revenue each year. What is Oxford BioMedica's official website? The official website for Oxford BioMedica is http://www.oxfordbiomedica.co.uk. How can I contact Oxford BioMedica? Oxford BioMedica's mailing address is Windrush Court, Transport Way, OXFORD, OX4 6LT, United Kingdom. The biopharmaceutical company can be reached via phone at +44-1865-783000. MarketBeat Community Rating for Oxford BioMedica (LON OXB)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 233 (Vote Outperform)Underperform Votes: 286 (Vote Underperform)Total Votes: 519MarketBeat's community ratings are surveys of what our community members think about Oxford BioMedica and other stocks. Vote "Outperform" if you believe OXB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OXB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/21/2019 by MarketBeat.com StaffFeatured Article: When is a capital gain realized?